cyclopentane has been researched along with Leukemia, Myeloid, Acute in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 8 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Celik, H; Challen, GA; Collins, TB; De Togni, ES; Fisher, DAC; Fulbright, MC; Kong, T; Laranjeira, ABA; Oh, ST; Ruzinova, M; Wong, AJ | 1 |
| Agelopoulos, K; Berdel, WE; Göllner, S; Klosner, J; Müller-Tidow, C; Rohde, C; Schliemann, C | 1 |
| Chen, Y; Sun, L | 1 |
| Arellano, ML; Baer, MR; Ball, BJ; Blum, W; Borate, U; Boyiadzis, MM; Burd, A; Byrd, JC; Chen, T; Collins, RH; Deininger, M; Druker, BJ; Duong, VH; Foran, JM; Foster, MC; Gana, TJ; Heerema, NA; Kaufmann, SH; Kovacsovics, T; Levine, RL; Lin, TL; Litzow, MR; Marcus, S; Martycz, M; Mims, AS; Odenike, O; Olin, RL; Patel, PA; Peterson, KL; Rosenberg, L; Saliba, AN; Schiller, GJ; Schneider, PA; Shoben, AB; Stefanos, M; Stein, EM; Stock, W; Traer, E; Walker, A; Yocum, AO | 1 |
| Hosono, N | 1 |
| Dutta, R; Jeng, MY; Mannis, GN; Tan, IT; Zhang, TY | 1 |
| Adès, L; Bell, J; Campelo, MD; Cerrano, M; Faller, DV; Fram, RJ; Friedlander, S; Graux, C; Liesveld, J; Lopez, PF; Radinoff, A; Sangerman, MA; Sekeres, MA; Selleslag, D; Tzvetkov, N; Watts, J; Zeidner, JF; Zhao, D | 1 |
| Bowen, S; Dai, Y; Faller, DV; Friedlander, S; Haikawa, K; Hua, Z; Kupperman, E; Kuroda, S; Nakai, K; Sedarati, F; Venkatakrishnan, K; Yamamoto, Y; Yuan, Y; Zhou, X | 1 |
| Arrate, MP; Boghaert, ER; Cojocari, D; Gorska, A; Hogdal, LJ; Huska, JD; Phillips, DC; Purkal, JJ; Ramsey, HE; Savona, MR; Smith, BN; Xiao, Y | 1 |
| Fathi, AT | 1 |
| Altman, JK; Bixby, DL; Blakemore, SJ; DeAngelo, DJ; Dezube, BJ; Erba, HP; Faessel, H; Giles, FJ; Hua, Z; Maris, M; Medeiros, BC; Sedarati, F; Swords, RT | 1 |
| Alachkar, H; Anghelina, M; Bloomfield, CD; Caligiuri, MA; Croce, CM; Curfman, J; Dorrance, A; Garzon, R; Guzman, ML; Huang, X; Khalife, J; Lee, LJ; Lee, RJ; Marcucci, G; Medeiros, BC; Mendler, JH; Neviani, P; Perrotti, D; Pichiorri, F; Radomska, HS; Santhanam, R; Saultz, J; Wang, H; Wu, YZ | 1 |
| Dai, H; Hess, AD; Karp, JE; Kaufmann, SH; Knorr, KL; Meng, XW; Schneider, PA; Smith, BD | 1 |
| Advani, AS; Beausoleil, SA; Carew, JS; Carraway, HE; Espitia, CM; Han, Y; Kelly, KR; Maciejewski, JP; Nawrocki, ST; Nazha, A; Possemato, A; Sekeres, MA; Visconte, V | 1 |
| Berger, AJ; Chalasani, S; Chen, S; Dai, Y; Dumur, CI; Ferreira-Gonzalez, A; Grant, S; Kmieciak, M; Leng, Y; Li, L; Lin, H; Povirk, L; Rahmani, M; Rizzo, KA; Zhang, Y; Zhou, L | 1 |
| Altman, JK; Anwer, F; DeAngelo, DJ; Dezube, BJ; Erba, HP; Faessel, H; Giles, FJ; Hua, Z; Maris, M; Medeiros, BC; Sedarati, F; Stein, H; Swords, RT; Watts, J | 1 |
| Finn, LE; Foran, JM; Hess, AD; Karp, JE; Kaufmann, SH; Knorr, KL; Smith, BD | 1 |
| Carew, JS; Garnsey, JJ; Giles, FJ; Kelly, KR; Mahalingam, D; Medina, E; Nawrocki, ST; O'Dwyer, M; Oberheu, K; Padmanabhan, S; Smith, PG; Swords, RT | 1 |
| Li, Y; Sun, Y; Tan, M; Xi, N; Yang, R | 1 |
1 review(s) available for cyclopentane and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
[New therapeutic agents for acute myeloid leukemia].
Topics: Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Drug Approval; Flavonoids; Glycine; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Sulfonamides; United States; United States Food and Drug Administration | 2019 |
6 trial(s) available for cyclopentane and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Topics: Aged; Azacitidine; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Pyrimidines; Tumor Suppressor Protein p53 | 2023 |
Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies.
Topics: Aged, 80 and over; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Disease-Free Survival; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Pyridines; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate | 2020 |
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Pyrimidines | 2021 |
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Azacitidine; Cyclopentanes; Drugs, Investigational; Global Burden of Disease; Humans; Incidence; International Cooperation; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Myelodysplastic Syndromes; Pharmacology, Clinical; Pyrimidines; Translational Research, Biomedical; Ubiquitin-Activating Enzymes; United States | 2021 |
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Cyclopentanes; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Multiple Organ Failure; Myelodysplastic Syndromes; Pyrimidines; Ubiquitin-Activating Enzymes | 2015 |
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Cyclopentanes; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; NEDD8 Protein; Pyrimidines; Young Adult | 2017 |
12 other study(ies) available for cyclopentane and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition.
Topics: Animals; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Mice; Myeloproliferative Disorders; Primary Myelofibrosis; Pyrimidines | 2022 |
Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia.
Topics: Azacitidine; Chemokine CXCL12; Combined Modality Therapy; Cyclopentanes; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; NEDD8 Protein; Pre-B-Cell Leukemia Transcription Factor 1; Pyrimidines; RNA Interference; Signal Transduction | 2021 |
Inhibition of NEDD8 NEDDylation induced apoptosis in acute myeloid leukemia cells via p53 signaling pathway.
Topics: Apoptosis; Cell Line, Tumor; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; NEDD8 Protein; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53; Ubiquitin-Conjugating Enzymes | 2022 |
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Pyrimidines; Sulfonamides | 2022 |
Pevonedistat, a new partner for 5-azacitidine.
Topics: Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; NEDD8 Protein; Pyrimidines | 2018 |
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
Topics: Animals; Apoptosis; Blotting, Western; Cell Differentiation; Cell Proliferation; Chromatin Immunoprecipitation; Cyclopentanes; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Monocytes; NEDD8 Protein; NF-kappa B; Promoter Regions, Genetic; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tandem Repeat Sequences; Tumor Cells, Cultured; Ubiquitins; Xenograft Model Antitumor Assays | 2015 |
MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cyclopentanes; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrimidines; RNA Interference; RNA, Small Interfering; Sulfonamides; Up-Regulation | 2015 |
Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.
Topics: Azacitidine; Cell Line, Tumor; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Neoplasm Proteins; Proteomics; Pyrimidines | 2016 |
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Cell Cycle Proteins; Cells, Cultured; Checkpoint Kinase 1; Cyclopentanes; DNA Damage; DNA Repair; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasm Proteins; NF-kappa B; Nuclear Proteins; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; RNA, Small Interfering; S Phase Cell Cycle Checkpoints; Sulfonamides; U937 Cells; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2016 |
Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.
Topics: Cell Count; Cell Death; Cell Survival; Cyclopentanes; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines | 2017 |
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cullin Proteins; Cyclopentanes; DNA Damage; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; NEDD8 Protein; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrimidines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Ubiquitins; Xenograft Model Antitumor Assays | 2010 |
Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclopentanes; Drug Interactions; Embryonic Stem Cells; Enzyme Activation; Enzyme Inhibitors; Female; Gene Deletion; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Male; Mice; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Tretinoin; Ubiquitin-Protein Ligases | 2011 |